You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

EVENTS

EIGHT, the global educational initiative on Hemophilia A and its treatment

Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

read more 

EVENTS

Kedrion Biopharma participates in the Mother and Child Conference in Moscow

A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

read more 

EVENTS

Kedrion Joins Annual PNS Conference on Neurology

The company took part in the event with a booth and a delegation of 40 int’l guests

read more 
  1. CORPORATE - 12-10-2015

    Kedrion supports Fondazione Paracelso's activities in Afghanistan

    Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries

    read more 
  2. CORPORATE - 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 
  3. CORPORATE - 21-09-2015

    Cash Tender Offer for Notes due 24 April 2019

    Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019

    read more 
  4. CORPORATE - 20-07-2015

    KEDPlasma welcomes donors to its new Augsburg collection center

    Plasma collected in Germany is essential to Kedrion Biopharma’s plasma-derived therapies

    read more 

Pages

For more information please contact: pressoffice@kedrion.com